HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sheila K Pierson Selected Research

Castleman Disease (Castleman's Disease)

4/2022Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
1/2022Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
10/2021Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
3/2021Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
1/2021Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
1/2020Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
1/2019Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
1/2019Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
1/2018Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sheila K Pierson Research Topics

Disease

9Castleman Disease (Castleman's Disease)
04/2022 - 01/2018
7Thrombocytopenia (Thrombopenia)
04/2022 - 01/2018
7Edema (Dropsy)
04/2022 - 01/2018
6Fever (Fevers)
04/2022 - 01/2019
3Fibrosis (Cirrhosis)
04/2022 - 01/2018
3Primary Myelofibrosis (Myelosclerosis)
01/2022 - 01/2019
3Inflammation (Inflammations)
01/2021 - 01/2019
2Cytopenia
04/2022 - 01/2019
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
04/2022 - 01/2022
2Autoimmune Lymphoproliferative Syndrome
01/2022 - 01/2020
2Weight Loss (Weight Reduction)
10/2015 - 08/2015
1Hyperplasia
04/2022
1Lymphadenopathy
04/2022
1Hypergammaglobulinemia (Hyperimmunoglobulinemia)
04/2022
1Thrombocytosis (Thrombocythemia)
04/2022
1Neoplasms (Cancer)
10/2021
1Multi-centric Castleman's Disease
10/2021
1Communicable Diseases (Infectious Diseases)
10/2021
1Renal Insufficiency (Renal Failure)
10/2021
1Disease Progression
01/2018
1Cytokine Release Syndrome
01/2018
1Type 2 Diabetes Mellitus (MODY)
10/2015
1Urinary Incontinence
08/2015
1Morbid Obesity
08/2015

Drug/Important Bio-Agent (IBA)

6Reticulin (Reticular Fiber)IBA
04/2022 - 01/2018
4CytokinesIBA
04/2022 - 01/2019
4Interleukin-6 (Interleukin 6)IBA
04/2022 - 01/2018
2C-Reactive ProteinIBA
04/2022 - 01/2019
2Sirolimus (Rapamycin)FDA Link
01/2022 - 01/2020
1Mechanistic Target of Rapamycin Complex 1IBA
01/2022
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
03/2021
1siltuximabIBA
01/2019
1Biological ProductsIBA
01/2019
1Monoclonal AntibodiesIBA
01/2019
1ChemokinesIBA
01/2018
1Immunoglobulins (Immunoglobulin)IBA
01/2018
1Insulin (Novolin)FDA Link
10/2015

Therapy/Procedure

2Bariatric Surgery
10/2015 - 08/2015
1Therapeutics
01/2019
1Precision Medicine
01/2019
1Gastric Bypass (Roux-en-Y Gastric Bypass)
10/2015